Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04862078

Shared Decision Making in Surveillance for Distant Metastasis in Breast Cancer

In this study, clinical impacts of shared decision making between physicians and patients in strategy of surveillance for asymptomatic patients who ended the primary treatments on quality of life would be investigated

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

20 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Seoul National University Hospital

Seoul, 03080, South Korea

About this study

[Background]

  • Shared decision making between patients and physicians when breast cancer patients encounter decision making in the initial treatment process has already been included in the recommendations for breast cancer treatment in each country. However, in the follow-up stage using various imaging tests after the initial breast cancer treatment, the evidence of decision making is very poor and the patient who understands this well and actively participates in the process of deciding the follow-up strategy are almost none.
  • Major guidelines including NCCN, ASCO and ESMO recommend surveillance with routine imaging such as sonography and mammography, and does not recommend advanced imaging tests for asymptomatic patients. These guidelines are based on two prospective randomized trials conducted in 1994. Despite many international medical recommendations, many institutions around the world are increasingly using distant metastasis tests in belief of improving the survival rate through early detection of distant metastasis and of improving the emotional stability of doctors and patients.
  • In this study, clinical impacts of shared decision making in strategy of surveillance for asymptomatic patients on quality of life would be investigated by prospective randomized pragmatic trial. Additionally, oncological results would be analyzed and real world data of patients preference would be gathered

[Study design] Prospective, single-institutional, randomized pragmatic trial

[Statistical considerations] With 5% significance level and 90% power, 132 patients are needed in each group. Assuming a 28% drop out rate, 368 patients need to be recruited.

[Randomizations] Web-based randomization would be conducted stratified to subtypes.

[Objectives]

  • Primary objective
  • QoL (when enrollment, after 1 and 2 year - FACT-B score)
  • Secondary objectives
  • Depression - anxiety scale (HADS score)
  • Recurrence-free survival
  • Patients' preference for surveillance in SDM group
  • Cross over rate in SDM group

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women between 20-70 years
  • Invasive unilateral breast carcinoma with histological confirmation
  • History of invasive breast cancer
  • TMN stage I-II according to AJCC 7th
  • Histologically or radiologically no suspicion of distant metastases
  • Performance status corresponding to ECOG grade 0-2
  • No psychological and geographical restriction in follow-up
  • Written informed consent

Exclusion criteria

  • History of any cancer in the previous 5 years
  • Bilateral breast cancer
  • Male breast cancer
  • Patients who are planning for surveillance in other institutions
  • Unable to understand and fill out questionnaires

Treatment and study plan

Shared decision making

Diagnostic Test

Shared decision making and decide surveillance strategy between "standard follow-up according to the institutional practice and decide what to do advanced imagings for surveillance" and "guideline-based surveillance"

Usual Care

Diagnostic Test

standard follow-up according to the institutional practice

Primary outcomes

  1. Quality of life (QoL), Depression-anxiety scale

    Time frame: At the point of enrollment

    Evaluated QoL with Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire

  2. Quality of life (QoL), Depression-anxiety scale

    Time frame: After 6 month of enrollment

    Evaluated QoL with Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire

  3. Quality of life (QoL), Depression-anxiety scale

    Time frame: After 1 year of enrollment

    Evaluated QoL with Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire

  4. Quality of life (QoL), Depression-anxiety scale

    Time frame: After 2 year of enrollment

    Evaluated QoL with Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire

Secondary outcomes

  1. Rate of patients who choose guideline-dependent surveillance rather than advanced imaging-dependent in SDM group

    Time frame: 6 month

    Rate of patients who choose guideline-dependent surveillance in SDM group (Patients' preference for surveillance)

  2. Cross over rate in SDM group

    Time frame: 2 years

    Evaluated Patients' cross-over rate in SDM group

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

Shared Decision Making in Follow-up Imaging Surveillance for Distant Metastasis in Treated Breast Cancer Patients [SMART-FU]: A Prospective, Single-institution, Randomized Pragmatic Trial

Acronym: SMART-FU

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Apr 27, 2021
Registry last updated
Jul 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.